Ironwood Pharmaceuticals IRWD
Valuation
Multiples measured against the stock's own five-year history
Around its usual level · 55th percentile, 5-year average -9.0x
#230 of 2992 stocks by PE (1 = cheapest)
Near the bottom of its 5-year range · 0th percentile, 5-year average -0.8x
Around its usual level · 40th percentile, 5-year average 2.8x
#2552 of 5156 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | -8.23 | – | -0.78 | 0% (cheaper than usual) | – |
| PE | 5.37 | 3.63 | -9.05 | 55% (pricier than usual) | #230 of 2992 (1 = cheapest) |
| PS | 2.00 | 1.62 | 2.76 | 40% (cheaper than usual) | #2552 of 5156 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on IRWD.
Sign in to join the discussion.